Dec 09, 2023  
2023-2024 College Catalog 
    
2023-2024 College Catalog
Add to Portfolio (opens a new window)

CRC 201 - Clinical Research Regulatory Compliance

3 Credits, 3 Contact Hours
3 lecture periods 0 lab periods

Introduction to the Food and Drug Administration (FDA) regulatory process and regulatory requirements for clinical research. Includes an overview of the role and function of the FDA, the drug development process, preparation and maintenance of an Investigational New Drug (IND), regulatory documentation, safety reporting, and Good Clinical Practices (GCPs).

Recommendation: Completion or concurrent enrollment in CRC 101 . If any recommended course is taken, see a financial aid or Veteran’s Affairs advisor to determine funding eligibility as appropriate.
Information: Students must be admitted to or have conditional status of the Clinical Research AAS or Post-Degree Certificate program or obtain the consent of the instructor before enrolling in this course.
Button linking to AZ Transfer course equivalency guide    button image Prior Learning and link to PLA webpage

Course Learning Outcomes
  1. Discuss the historical events that precipitated the development of governmental regulatory processes for investigational products
  2. Identify Good Clinical Practice (GCP) Guidelines
  3. Summarize the principle methods of balancing risk and benefit through selection of study participants
  4. Differentiate between a sponsor audit, an IRB audit, and an FDA inspection
  5. Identify the key steps in the drug development/device approval process

Outline:
  1. The Role, Function, and Organization of the Food and Drug Administration (FDA)
    1. Brief history of the FDA
    2. 3-part mission of the FDA
    3. Definitions for major product characteristics
    4. FD&C Act, Code of Federal Regulations, FDA and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidance
    5. How to contact and interact with the agency
    6. Agency role in oversight of clinical studies
  2. Compliance with Good Clinical Practices
    1. Overview of ICH Guidelines E.6
    2. Monitoring of clinical research-sponsor obligations and expectations
    3. Routine GCP audits associated with sponsor marketing applications
    4. Handling, understanding, and responding to FDA Form 483
    5. FDA GCP “for cause” audits
    6. FDA’s fraud policy
    7. Regulatory sanctions for noncompliance
  3. Regulatory Documentation Requirements for Clinical Studies
    1. Completion of Form FDA 1572 (Investigator’s commitment)
    2. Required Investigator and sub investigator information
    3. Institutional Review Board Approvals as required
    4. Types of studies that require Financial Disclosures
    5. Informed Consent and Re-consent process
    6. Preparation and maintenance of Site Regulatory Binders
    7. Study medication storage and accountability
    8. Archiving of study-related documentation
    9.     Documents required before drug can be shipped
  4. Safety Reporting
    1. Routine adverse event reporting
    2. When is an AE a SAE?
    3. SAE reporting obligations to the sponsor, IRB, and other investigators
    4. How to submit 7- and 15-day IND safety reports for SAEs
    5. How to prepare follow-up reports and conduct ongoing safety review
    6. Termination of clinical studies for safety reasons
    7. Use of the Med Watch and Council for the International Organization of Medical Science (CIOMS) safety reporting forms
    8. Drug Safety Monitoring boards
    9. New FDA safety initiatives


Effective Term:
Full Academic Year 2018/19



Add to Portfolio (opens a new window)